What is Sofie Biosciences?
Sofie Biosciences is at the forefront of transforming clinical diagnostics and therapeutics by enhancing the adoption and application diversity of theranostics. The company aims to demystify and reduce the cost and complexity traditionally associated with molecular imaging. By offering a comprehensive suite of imaging and radiochemistry systems, coupled with a robust radiopharmacy network and contract manufacturing capabilities for novel diagnostic and therapeutic agents, Sofie Biosciences is dedicated to improving patient health outcomes through innovative medical solutions.
How much funding has Sofie Biosciences raised?
Sofie Biosciences has raised a total of $55.6M across 6 funding rounds:
Series A
$5M
Grant
$1.5M
Private Equity
$3.7M
Series B
$16M
Debt
$2M
Series C
$27.4M
Series A (2013): $5M with participation from MRM Capital, Cycad Group, and Tata Industries
Grant (2014): $1.5M led by MRM Capital and Cycad Group
Private Equity (2016): $3.7M supported by Artiman Managment, LLC
Series B (2018): $16M featuring Mayor Richard Riordan
Debt (2020): $2M backed by PPP
Series C (2020): $27.4M with participation from Jubilant Pharma Limited
Key Investors in Sofie Biosciences
MRM Capital
MRM Capital Holdings specializes in providing creative private equity solutions and strategic advisory services to maximize investment opportunities. The firm focuses on raising capital and debt solutions for a variety of investment opportunities, particularly in real estate and distressed debt.
Cycad Group
Cycad Group is focused on investing in technology across various sectors, including healthcare and energy. Their portfolio includes companies developing innovative solutions such as medical devices for treating bloodstream infections, biopharmaceuticals for cancer therapies, and advanced battery technologies.
Artiman Managment, LLC
Artiman Management LLC is an investment firm that focuses on innovative companies in various sectors. Their portfolio includes ApplyBoard, an AI-enabled marketplace for international students; Virsec, which specializes in securing corporate applications; CellMax Life, a precision cancer blood-testing company; and Visby Medical, which develops diagnostic platforms for illness.
What's next for Sofie Biosciences?
With its recent capital infusion, Sofie Biosciences is poised to further scale its operations and accelerate the development and deployment of its theranostic technologies. The company's focus on removing cost and complexity barriers suggests a strategy aimed at broader market penetration and increased accessibility of advanced diagnostic and therapeutic tools. Future initiatives will likely involve expanding its radiopharmacy network, enhancing its imaging and radiochemistry systems, and potentially forging new partnerships to broaden the application diversity of its offerings, solidifying its position as a leader in theranostics.
See full Sofie Biosciences company page
